This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Maternal Vaccination
Adults
Preparation
Private Market
Useful Resources
Useful
ResourcesVideosMaterials

ABRYSVO®▼(Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Prescribing Information for the United Kingdom click here.  

Respiratory Syncytial Virus (RSV) VaccinationThe use of this vaccine should be in accordance with official recommendations.1ABRYSVO is indicated for:1
  • Passive protection against lower respiratory tract disease (LRTD) caused by RSV in infants from birth through 6 months of age following maternal immunisation during pregnancy.
  • Active immunisation for the prevention of LRTD caused by RSV in individuals 60 years of age and older.
  • Active immunisation for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
The use of this vaccine should be in accordance with official recommendations.1

ABRYSVO is offered as part of the RSV National Immunisation Programme and is also available privately.2,3 ABRYSVO Maternal Vaccination Home PageLoading
    ABRYSVO Adult  Loading
      Useful  Loading
        Tools and resources to support your clinical decision making with ABRYSVO

         Maternal Infographic

        Download the maternal infographic to understand how vaccination during pregnancy can help protect infants from birth through 6 months of age from RSV-associated LRTD. 

         Access ResourceLoading         RSV Expert Video Series

        Explore our RSV expert video series to gain insights from global specialists on the symptoms, transmission, and burden of RSV infection on your patients. 

        Access ResourcesLoading         Useful Resources

        Visit the ABRYSVO resources section for e-modules, bite size videos, preparation guidance, a maternal vaccination patient conversation guide and other useful downloadable materials.

        Access ResourcesLoading        Preparation, dosing, administration, storage and co-administration

        Click here for information about the preparation, dosing, administration, storage and co-administration of ABRYSVO.

        Bitesize videos exploring who is most at risk of RSV, its prevalence and the broader impact on healthcare systems and hospitalisations

        Uncover who is most at risk of serious outcomes from an RSV infection. 

        Watch more videos in this seriesLoading

        Learn more about how RSV infection affects global healthcare systems and hospitalisation of patients in the UK. 

        Watch more videos in this seriesLoading

        Guidance on implementing the RSV National Immunisation Programme across the UK

        Below are the decisions made by the UKHSA and NHS across the devolved nations about how the RSV programme should be delivered. 

         

         England
        VISIT: GOV.UK Page
        Loading         Scotland VISIT: Adult NHS Inform Loading VISIT: Pregnancy NHS InformLoading         Wales
        VISIT: Public Health Wales 
        Loading        Northern Ireland VISIT: Department of Health NI Loading VISIT: Department of Health NI Older Adults 2026Loading        VISIT: Green Book Chapter 27a on RSVLoading
        For any further questions or information regarding the programme, please speak to your vaccine commissioner.

        The use of this vaccine should be in accordance with official recommendations. 

        1. ABRYSVO (Respiratory Syncytial Virus Vaccine [bivalent, recombinant]) Summary of Product Characteristics for the United Kingdom. Available at: https://www.medicines.org.uk/emc/product/15309.

        2. United Kingdom Health Security Agency (UKHSA). Respiratory syncytial virus (RSV) vaccination programme. Available at: https://www.gov.uk/government/collections/respiratory-syncytial-virus-rsv-vaccination-programme. [Accessed March 2026].

        3. Respiratory Syncytial Virus. The Green Book Chapter 27a. Available at: https://www.gov.uk/government/publications/respiratory-syncytial-virus-the-green-book-chapter-27a. [Accessed March 2026].

        PP-A1G-GBR-0461. March 2026

        Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

        for MHRA Yellow Card in Google Play or Apple App Store

         

        Adverse events should also be reported to Pfizer Medical Information on 01304 616161

        PfizerPro Account

        To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

        Sign In or RegisterAccountSign Out

        This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

         

        This website is brought to you by Pfizer Limited, a company registered in England 

        and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

         

        Copyright © 2026 Pfizer Limited. All rights reserved.

         

        VAT registration number GB201048427

        PP-UNP-GBR-13934. January 2026
        For UK Healthcare Professionals*

        These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

        I confirm that I am a healthcare professional* resident in the United Kingdom.

        If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

        *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

        PP-UNP-GBR-13971. December 2025

        YesNo
        You are now leaving PfizerPro​​​​​
        ​
        You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

        Pfizer accepts no responsibility for the content or services of the linked site.

        PP-UNP-GBR-12070. April 2025​​​​​​​
        ​​​​​​​
        You are now leaving PfizerPro

        ​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

        Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

        PP-UNP-GBR-12107. April 2025
        ​​​​​​​